Ochre Bio
PrivateLast Round
Series A
Oct 10, 2022
Total Funding Raised
$39.75M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Ochre Bio is a biotechnology company that develops RNA-based therapies for chronic liver diseases using a discovery platform that integrates machine learning, genomic phenotyping, and perfused human donor livers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ochre Bio Comparables
Compare Ochre Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Multiomic Health | 75% | |
| Quotient Therapeutics | 75% | |
| Insitro | 70% |
Ochre Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Oct 10, 2022 | ||||
| Seed | Jun 16, 2021 | ||||
| Pre Seed | Mar 18, 2020 |
Ochre Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Backed VC | Series A, Seed |
| LifeLink Ventures | Series A |
| Khosla Ventures | Series A, Seed |
| Hoxton Ventures | Seed |
| Hermes-Epitek | Series A, Seed |
| Lifeforce Capital | Series A |
| EIT Health | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors grew 34% MoM, reaching 4.4K.
- Jun 30, 2025
Quin Wills appointed as the new Chief Executive Officer.
Ochre Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Ochre Bio's valuation, stock price, and market status.
Is Ochre Bio a public or private company?
Ochre Bio is a private company.
What is the current stock price of Ochre Bio?
Ochre Bio is a private company with no public stock price. No recent secondary market data is available.
How much is Ochre Bio worth (valuation)?
Valuation information for Ochre Bio is not publicly available.
Can I buy Ochre Bio stock?
Ochre Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Ochre Bio's last funding round?
Ochre Bio's most recent funding round was Series A on October 10, 2022.
Who are the main investors in Ochre Bio?
Key investors in Ochre Bio include Khosla Ventures, Y Combinator.
Will Ochre Bio IPO soon?
No public IPO plans have been announced for Ochre Bio.
How can I track Ochre Bio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Ochre Bio's secondary market activity and sign up for updates.